Standout Papers

RECIST 1.1—Update and clarification: From the RECIST committee 2016 2026 2019 2022 1.5k
  1. RECIST 1.1—Update and clarification: From the RECIST committee (2016)
    Lawrence H. Schwartz, Saskia Litière et al. European Journal of Cancer
  2. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics (2017)
    Lesley Seymour, Jan Bogaerts et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 9 from Science/Nature 71 standout
Sub-graph 1 of 22

Citing Papers

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 Standout
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
2023 Standout
1 intermediate paper

Works of Robert Ford being referenced

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
RECIST 1.1—Update and clarification: From the RECIST committee
2016 Standout

Author Peers

Author Last Decade Papers Cites
Robert Ford 896 1387 2090 19 3.6k
Charles Ferté 1492 1456 2400 77 4.1k
Laura Meyer 564 1543 1874 10 4.4k
Wendy Hayes 849 993 1078 47 2.5k
Samy Ammari 1791 1403 2626 110 4.4k
Robert K. Brookland 604 1595 1885 7 4.3k
Cornelius J. McGinn 545 1472 1558 38 3.2k
Deborah Kuk 341 1806 2694 78 4.4k
Kirsten B. Goldberg 366 1239 2625 66 4.3k
Roger Ove 488 1715 1943 35 4.0k
Donna M. Gress 643 2009 2405 11 5.3k

All Works

Loading papers...

Rankless by CCL
2026